This study validates a novel plasma p-tau217 immunoassay for detecting Alzheimer's disease neuropathology. Across three independent cohorts, the assay demonstrated high diagnostic accuracy in differentiating Alzheimer's from other neurodegenerative conditions, supporting its clinical utility.